MenBioVax

**MenBioVax** is an investigational immunostimulant vaccine developed by ImmunoBiology Ltd. (also referred to as ImmBio), designed as a multivalent formulation containing a mixture of protein antigens to target meningococcal disease. It aims to provide protection against multiple *Neisseria meningitidis* serogroups, potentially including ACYW and others, using a proprietary ImmBioVax™ technology platform for next-generation vaccines against serious infectious diseases like meningococcus and pneumococcus. The vaccine's purified clinical product (PCP) has been reported to fulfill WHO requirements and was used in a MenACWY vaccine context, though specific components, dosing, and efficacy data remain limited.[5][7][12][15]